This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Breakthrough Cancer Pain

Chronic background pain is a common symptom for patients with cancer.1

Many patients also suffer transient exacerbations of pain, known as breakthrough cancer pain (BTcP).2

BREAKTHROUGH CANCER PAIN

Provided by
KKI NewCo (known as Grünenthal Meds)

Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.5

Click here for prescribing and adverse event reporting information.

LEARN MORE

BREAKTHROUGH CANCER PAIN

Provided by
KKI NewCo (known as Grünenthal Meds)

PecFent® is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.6

Click here for prescribing and adverse event reporting information.

LEARN MORE

Average:

  • References

    1. Portenoy RK et al. Prim Care & Cancer 1991; April:27-33.

    2. Davies AN et al. BMJ Support Palliat Care 2018;):1-9. Doi:10.1136/bmjspcare-2017-001467.

    3. Abstral® (fentanyl citrate) Summary of Product Characteristics.

    4. PecFent® Summary of Product Characteristics.

    KKI/UK/GEN/0120 November 2023